Division of Metabolic & Endocrine Products director
Executive Summary
Acting Division of Metabolic & Endocrine Products Director Mary Parks will hold the permanent position as of Aug. 6. Parks, former ODE II division deputy director and team leader for lipid-lowering drugs, was promoted to director following the departure of David Orloff Jan. 1 (1The Pink Sheet" Dec. 12, 2005, In Brief)...
You may also be interested in...
Orloff departs FDA
Metabolic & Endocrine Disorders Division Director David Orloff will step down Dec. 30 after 11 years with FDA to become the medical director of contract research organization Medpace, Inc. Orloff announced his resignation Nov. 29. Division Deputy Director Mary Parks will take over as acting director Jan. 1 until a permanent successor is named. Orloff, who oversaw FDA's review of Bristol-Myers Squibb's Pargluva, is one of several top officials to resign since summer, following the departures of Commissioner Lester Crawford and Office of Women's Health Director Susan Wood...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.